A utoimmune progesterone dermatitis (AIPD) is classified as a rare condition by the National Institutes of Health. 1 According to a 2003 review, approximately 50 cases of AIPD had been reported in literature since 1921. 2 It is an autoimmune phenomenon to endogenous progesterone that occurs in women of reproductive age, with or without a history of exogenous synthetic progestin exposure. [2] [3] [4] [5] [6] [7] Autoimmune progesterone dermatitis is typically characterized by cyclical premenstrual flares of polymorphous dermatologic manifestations that begin during the luteal phase of the menstrual cycle when progesterone levels peak, and it subsides a few days into menses with the decline of progesterone levels. Previous case reports have documented patient disease progression to a life-threatening anaphylactic cycle of reactions, which has been referred to as "progesterone-induced anaphylaxis." 2 Definitive management strategies for this possibly debilitating disease have not been well studied. However, successful diagnostic and treatment modalities exist.
Once diagnosed, patients with AIPD have a favorable prognosis, with improved quality of life. However, most patients with AIPD endure their symptoms for years without effective workup, primarily a result of lack of disease awareness in the medical community.
The present case series seeks to describe AIPD to medical providers of premenopausal women so that patients may be appropriately treated. This knowledge is especially important considering AIPD's potential to progress to life-threatening anaphylaxis.
Progressively Worsening Cyclic Rash: Diagnosis and Approach to Care
CASE REPORT
The Relative eosinophilia presents in cutaneous symptoms in many patients reported through the years, and reports suggest that progesterone may induce mast cell degranulation by its nature. 8, 15 Whether the eosinophilia is a random correlation with the disease or a direct cause is unknown. 8 In investigation of the disease's cutaneous histopathology, superficial perivascular mixed inflammation is the most consistent histologic evidence, 9,10 with other findings ranging from nonspecific changes to specific dermatoses like erythema multiforme. 10 Infiltration of the dermis in cutaneous lesions may also consist of lymphocytic or mixed eosinophil, neutrophil, or mast cellularity. complex-induced vasculitic reactions. 18 In addition,
Stephens et al, 19 among others, suggest the use of tamoxifen for reducing the severity of AIPD. 3, [6] [7] [8] 11, 12, 17 The latter 2 methods have a high incidence of adverse effects, particularly tamoxifen's effect on menopausal symptoms and danazol's antiestrogenic effect on bone metabolism. For more severe cases of AIPD, such as patients with cyclic anaphylactic symptoms, bilateral oophorectomy should be considered. As reported by Ródenas et al, 5 therapeutic oophorectomy for this condition should be considered when conservative treatment has failed.
Premenopausal women may then be given oral, topical, transdermal, or pellet estrogen replacement, with monitoring of the endometrial thickness in patients with an intact uterus.
Osteopathic Considerations
Increasing lymphatic drainage and return to the venous system through manual techniques (eg, lymphatic pump) have long been practiced and are only recently documented in the practice of osteopathic medicine.
Osteopathic manipulative treatment has been used to reduce pain and edema, increase range of motion and functionality, and decrease inflammation and promotion of cytokine release in patients with chronic inflammatory diseases. 20, 21 Patients who present with AIPD may benefit from lymphatic pump techniques to decrease the inflammatory response, decrease the severity of symptoms, and improve the circulating immune system.
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